Cargando…
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
BACKGROUND: The PD-1/PD-L1 pathway plays critical roles in tumour immunology, and serves as an immune-based therapeutic target. Less is known regarding PD-L2, another ligand of PD-1, and its relation to clinical outcome in human cancers. METHODS: We used a database of 437 surgically and 100 endoscop...
Autores principales: | Okadome, Kazuo, Baba, Yoshifumi, Nomoto, Daichi, Yagi, Taisuke, Kalikawe, Rebecca, Harada, Kazuto, Hiyoshi, Yukiharu, Nagai, Yohei, Ishimoto, Takatsugu, Iwatsuki, Masaaki, Iwagami, Shiro, Miyamoto, Yuji, Yoshida, Naoya, Watanabe, Masayuki, Komohara, Yoshihiro, Shono, Takashi, Sasaki, Yutaka, Baba, Hideo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217865/ https://www.ncbi.nlm.nih.gov/pubmed/32210369 http://dx.doi.org/10.1038/s41416-020-0811-0 |
Ejemplares similares
-
PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
por: Okadome, Kazuo, et al.
Publicado: (2021) -
Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
por: Yamashita, Kohei, et al.
Publicado: (2019) -
Lysyl oxidase impacts disease outcomes and correlates with global DNA hypomethylation in esophageal cancer
por: Kalikawe, Rebecca, et al.
Publicado: (2019) -
Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma
por: Liu, Yang, et al.
Publicado: (2020) -
Indoleamine 2, 3‐dioxygenase 1 promoter hypomethylation is associated with poor prognosis in patients with esophageal cancer
por: Kiyozumi, Yuki, et al.
Publicado: (2019)